Boehringer Ingelheim congratulates Prof. Brian Kobilka of Stanford University, who was awarded the Nobel Prize in chemistry. Prof. Kobilka has made ground-breaking contributions to the understanding of how cells sense information from the autonomic nervous system and convert them into cellular responses.

UCB announced that it has launched a third collaborative research project with Harvard that builds upon the innovative Research Alliance they both signed in 2011. The third research project named 'Mining the Human Microbiome' will be headed by Christophe Benoist, M.D., Ph.D., Dennis Kasper, M.D., and Diane Mathis, Ph.D., all Professors in the Division of Immunology in the Department of Microbiology and Immunobiology at Harvard Medical School.

World's largest pneumococcal mass vaccination programme is expected to protect up to 4.8 million children in Pakistan from pneumococcal disease. Pakistan is the first GAVI eligible country in south Asia to introduce pneumococcal vaccines.

Sanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with ELIQUIS® compared to warfarin in the ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation.

Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) approved Stivarga® (regorafenib) tablets for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with currently available therapies (including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if KRAS wild type, an anti-EGFR therapy).

Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.